Trade Synlogic - SYBX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.08 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.6 |
Open | 1.57 |
1-Year Change | 220.41% |
Day's Range | 1.57 - 1.62 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 1.60 | 0.02 | 1.27% | 1.58 | 1.60 | 1.58 |
Jul 24, 2024 | 1.69 | 0.16 | 10.46% | 1.53 | 1.69 | 1.48 |
Jul 23, 2024 | 1.64 | 0.00 | 0.00% | 1.64 | 1.66 | 1.55 |
Jul 22, 2024 | 1.61 | 0.14 | 9.52% | 1.47 | 1.61 | 1.47 |
Jul 19, 2024 | 1.52 | -0.06 | -3.80% | 1.58 | 1.58 | 1.49 |
Jul 18, 2024 | 1.58 | 0.04 | 2.60% | 1.54 | 1.60 | 1.53 |
Jul 17, 2024 | 1.57 | -0.01 | -0.63% | 1.58 | 1.63 | 1.48 |
Jul 16, 2024 | 1.54 | 0.06 | 4.05% | 1.48 | 1.59 | 1.48 |
Jul 15, 2024 | 1.48 | 0.07 | 4.96% | 1.41 | 1.51 | 1.41 |
Jul 12, 2024 | 1.42 | -0.01 | -0.70% | 1.43 | 1.48 | 1.38 |
Jul 11, 2024 | 1.43 | 0.00 | 0.00% | 1.43 | 1.43 | 1.38 |
Jul 10, 2024 | 1.43 | 0.00 | 0.00% | 1.43 | 1.43 | 1.43 |
Jul 9, 2024 | 1.43 | 0.00 | 0.00% | 1.43 | 1.43 | 1.42 |
Jul 8, 2024 | 1.43 | 0.02 | 1.42% | 1.41 | 1.43 | 1.40 |
Jul 5, 2024 | 1.44 | 0.00 | 0.00% | 1.44 | 1.47 | 1.44 |
Jul 3, 2024 | 1.43 | 0.04 | 2.88% | 1.39 | 1.45 | 1.39 |
Jul 2, 2024 | 1.41 | -0.06 | -4.08% | 1.47 | 1.47 | 1.37 |
Jul 1, 2024 | 1.46 | -0.01 | -0.68% | 1.47 | 1.51 | 1.43 |
Jun 28, 2024 | 1.45 | -0.04 | -2.68% | 1.49 | 1.51 | 1.34 |
Jun 27, 2024 | 1.49 | 0.00 | 0.00% | 1.49 | 1.53 | 1.43 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Synlogic Company profile
About Synlogic Inc
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the drug discovery and development of Synthetic Biotic medicines. Its product pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The Company's lead product candidate includes SYNB1618, which is an oral therapy for the treatment of PKU. Its other product candidate SYNB8802 is developed for the treatment of Enteric Hyperoxaluria. The Company developed Synthetic Biotic medicines to treat certain cancers that are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. It is developing SYNB1891 for the treatment solid tumors and lymphoma. The Company is conducting Phase II clinical trial with SYNB1618.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Synlogic Inc revenues increased from $545K to $1.8M. Net loss increased 2% to $60.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 18% to $13.4M (expense), Interest and investment income decrease of 84% to $210K (income).
Industry: | Biotechnology & Medical Research (NEC) |
301 Binney St Ste 402
CAMBRIDGE
MASSACHUSETTS 02142-1030
US
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com